NexturnBioscience Co. Ltd
Nexturn Co.,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. It provides CNC swiss-type automatic lathe products, high temperature display glass press equipment, and automatic line-up robots, as well as an intelligent intervention robot system based on robot 3D cardiovascular visualization technology. The company was formerly known as KMT Incorporated and chan… Read more
NexturnBioscience Co. Ltd (089140) - Total Liabilities
Latest total liabilities as of September 2025: ₩128.65 Billion KRW
Based on the latest financial reports, NexturnBioscience Co. Ltd (089140) has total liabilities worth ₩128.65 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NexturnBioscience Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how NexturnBioscience Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NexturnBioscience Co. Ltd Competitors by Total Liabilities
The table below lists competitors of NexturnBioscience Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Emmis Communications Corp
PINK:EMMS
|
USA | $102.08 Million |
|
Garuda Metalindo Tbk PT
JK:BOLT
|
Indonesia | Rp581.39 Billion |
|
Total Soft Bank Ltd
KQ:045340
|
Korea | ₩19.09 Billion |
|
TAPEX INC
KO:055490
|
Korea | ₩39.20 Billion |
|
Shinyoung Waco
KO:005800
|
Korea | ₩39.27 Billion |
|
RTRZY
OTCGREY:RTRZY
|
USA | $803.40 Million |
|
Bluerock Homes Trust Inc.
NYSE MKT:BHM
|
USA | $452.66 Million |
|
Antisense Therapeutics Limited
PINK:ATHJF
|
USA | $5.17 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down NexturnBioscience Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NexturnBioscience Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NexturnBioscience Co. Ltd (2014–2024)
The table below shows the annual total liabilities of NexturnBioscience Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩96.41 Billion | -9.03% |
| 2023-12-31 | ₩105.98 Billion | +15.22% |
| 2022-12-31 | ₩91.98 Billion | +99.04% |
| 2021-12-31 | ₩46.21 Billion | +1689.03% |
| 2020-12-31 | ₩2.58 Billion | -48.45% |
| 2019-12-31 | ₩5.01 Billion | -72.17% |
| 2018-12-31 | ₩18.01 Billion | +502.69% |
| 2017-12-31 | ₩2.99 Billion | -65.43% |
| 2016-12-31 | ₩8.64 Billion | +172.72% |
| 2015-12-31 | ₩3.17 Billion | -28.10% |
| 2014-12-31 | ₩4.41 Billion | -- |